Nominations Being Accepted For the Bio-it World 2011 Best Practices Awards

Jan. 27, 2011 - PRLog -- Needham, MA—Bio-IT World announces the 2011 Best Practices Awards program submission deadline is February 4, 2011.  Established in 2003, this prestigious peer-reviewed awards program recognizes outstanding examples of technology and strategic innovation—initiatives and collaborations that manifestly improve some facet of the R&D, drug development, or clinical trials process.

The deadline for entry in the program is February 4, 2011, and the 2011 winners will be revealed and honored at the Best Practices Awards dinner on Wednesday, April 13, 2011, in conjunction with the Bio-IT World Conference & Expo in Boston (http://www.bio-itworldexpo.com). They will also be profiled in the July/August 2011 issue of Bio-IT World.

“Our annual awards feature outstanding examples of innovation, new technologies and practices across the spectrum of biomedical research, drug development and clinical research—highlighting the tools and strategies that can make a difference in the conduct of basic and clinical research, speeding the drug discovery pipeline, and changing the way we generate, share and analyze data and knowledge,” says Kevin Davies, Ph.D., editor-in-chief, Bio-IT World.  “But it’s not just about recognizing individual organizations making exception contributions to biomedical research, it’s about spotlighting new ideas and “bio-IT” technologies that can benefit the industry as a whole.”

The awards attract a broad, international group of life science professionals from academia and industry, drug discovery and clinical, users and vendors responsible for developing and implementing innovative solutions for streamlining the drug development and clinical trial process. Bio-IT World's distinguished peer-review panel of judges has reviewed more than 400 entries in the program's history, with last year's more than 75 entries a record for the competition.

Entries will be accepted in eight categories: Basic Research; Drug Discovery & Development; Clinical Trials & Research; Translational & Personalized Medicine; IT & Informatics; Knowledge Management; Health-IT; and Manufacturing & Bioprocessing. Additional awards—the Editors’ Prize and the Judges’ Award—are also up for grabs.
Winners last year included MIT, FDA (nominated by GlobalSubmit), The Scripps Research Institute (nominated by SciQuest), Bristol-Myers Squibb, Centocor R&D (nominated by Recombinant Data Corp), PROOF/iCAPTURE Centre of Excellence, goBalto.com, Merck and Co., and the Royal Society of Chemistry. These organizations and projects were featured in the July/August 2010 issue of Bio-IT World as well as in the 2010 Best Practice Compendium.

For more information on the program and to download the entry form, please visit http://www.bio-itworld.com/bestpractices or contact Allison Proffitt, Bio-IT World’s Managing Editor at 617.233.8280 or aproffitt@healthtech.com.

For more information on the 2011 Bio-IT World Conference & Expo, please visit http://www.bio-itworldexpo.com.

About Bio-IT World (http://www.bio-itworld.com)
Part of the Cambridge Healthtech Institute Media Group (http://www.chimediagroup.com), Bio-IT World magazine is a bimonthly publication that life science and IT/informatics professionals continuously reference to find information, news, and commentary on indispensable technologies and business strategies.  Bio-IT World provides outstanding coverage of cutting-edge trends and technologies that impact the management and analysis of life sciences data, including next-generation sequencing, drug discovery, predictive and systems biology, informatics tools, clinical trials, and personalized medicine.

Cambridge Healthtech Media Group also hosts daily news and opinion at http://www.bio-itworld.com, a variety of e-newsletters, and a rich compendium of webinars and web symposia. Cambridge Healthtech Media Group is based in Needham, Mass.

# # #

Bio-IT World focuses on the tools and results of predictive biology, drug discovery, informatics, clinical trials, and personalized medicine as well as the strategic decisions made by companies in this area and the impact on the company’s performance.